Don't look for the logo to boost reputation, says Pfizer PR

Share this article:
Don't look for the logo to boost reputation, says Pfizer PR
Don't look for the logo to boost reputation, says Pfizer PR
Authenticity and earned media trump slick corporate ads when it comes to bolstering corporate reputation, said Pfizer's Sally Susman.

Speaking at a PR summit at Pfizer HQ yesterday, Susman, SVP and chief communications officer for Pfizer, emphasized the importance of “return on reputation” and said corporate ads don't work.

“If we pay, it's immediately tainted,” said Susman, describing the reputational challenges Big Pharma must contend with in terms of public reception. “I don't want my logo on things.” She noted that Edelman's annual Trust Barometer found public trust of healthcare providers plunged this year.

As an alternative, Susman pointed to Pfizer's “Maintain” program, which offers free prescriptions to customers that were laid off prior to January 1, 2009. The program was initiated by George Puente, a doctor and regional president of worldwide pharmaceuticals at Pfizer, who conceived of the idea and served as a spokesman for its launch. “George is not a slick spokesman,” said Susman, emphasizing the importance of authentic storytelling as a communication strategy.

Addressing the sour reputation of pharma, which the public views as “greedy, arrogant and deceitful people who care only about money,” Susman countered that Pfizer “does care about profits, but we spend a lot more time talking about science, health and prevention.”

Instead of focusing solely on ROI as a metric for successful PR, Susman suggested the addition of an ROR metric: return on reputation.

Susman was speaking at a conference hosted by ExL Pharma on July 27 – 28.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...